Actinogen Medical Limited (AU:ACW) has released an update.
Actinogen Medical Limited has released its financial results for the year ended June 30, 2024, while also developing Xanamem, a novel therapy aimed at treating neurological and neuropsychiatric disorders by regulating brain cortisol levels. The promising drug is currently in Phase 2 trials for Alzheimer’s and depression, with interim results expected in mid 2025. The company remains focused on addressing the significant unmet medical needs in cognitive health through their innovative approach.
For further insights into AU:ACW stock, check out TipRanks’ Stock Analysis page.
